Comparative Approach to Define Increased Regulatory T Cells in Different Cancer Subtypes by Combined Assessment of CD127 and FOXP3

Table 1

Patient characteristics for T_reg-cell assessment in peripheral blood.

(a) MGUS (peripheral blood)

ID	Gender	Age (yr)	Stage	Therapy	Paraprotein	Treg (%)
1	M	37	MGUS	no tx	IgG/λ	3.6
2	F	84	MGUS	no tx	IgA/κ	7.0
3	F	86	MGUS	no tx	IgG/κ	7.5
4	F	62	MGUS	no tx	IgA	6.0
5	M	52	MGUS	no tx	n.a.	6.8
6	F	79	MGUS	no tx	n.a.	2.4
7	M	65	MGUS	no tx	IgM/κ	8.0

(b) Multiple myeloma (peripheral blood)

ID	Gender	Age (yr)	Stage	Therapy	Paraprotein	Treg (%)
8	M	62	MM I A	M	IgG/κ	16.5
9	F	39	MM I A	VAD, CAD, M, BMT	IgG/κ	7.4
10	M	59	MM II A	no tx	IgG/κ	10.2
11	F	74	MM I A	no tx	IgG/λ	4.5
12	M	86	MM I A	no tx	IgG/κ	6.7
13	M	60	MM II A	VAD, CAD, M, BMT	IgG/κ	16.9
14	F	52	MM II A	VID, C	IgG/κ	4.4
15	M	59	MM II A	TAD, CAD, M, BMT	IgG/κ	8.6
16	F	67	MM II A	VAD, CAD, M, BMT	IgG/κ	22.2
17	M	53	MM II A	no tx	IgG/λ	8.0

(c) Chronic lymphocytic leukemia (peripheral blood)

ID	Gender	Age (yr)	Stage	Therapy	Treg (%)
18	m	72	CLL A	no tx	6.1
19	m	62	CLL A	no tx	5.7
20	f	73	CLL A	no tx	5.6
21	m	60	CLL B	no tx	9.8
22	f	55	CLL B	no tx	10.6
23	m	73	CLL B	no tx	16.4
24	m	64	CLL B	no tx	7.4
25	m	39	CLL C	no tx	15.3
26	m	60	CLL C	no tx	6.2
27	m	54	CLL C	no tx	6.4

(d) Colorectal cancer (peripheral blood)

ID	Gender	Age (yr)	Stage	Primary tumor	Sites of metastases	Treg (%)
28	f	43	D	Rectum	Liver, bone, pararectal, para-aortal lymph nodes	7.5/10.4
29	f	32	D	Colon	Liver, spleen, ovaries, pelvis, peritoneum	5.7/9.3
30	m	57	D	Rectum	Lung	5.7/9.9
31	m	66	D	Colon	Liver	5.0/6.2
32	m	75	D	Colon	Liver	9.0/4.8
33	f	44	D	Colon	Liver	9.9/3.3

(e) Healthy donors (peripheral blood)

ID	Gender	Age (yr)	Treg (%)
34	m	66	5.4
35	m	67	6.6
36	m	55	3.9
37	m	50	6.5
38	m	47	4.5
39	m	46	3.5
40	m	46	4.8
41	m	62	4.1
42	m	45	2.6
43	f	44	4.0

Patient characteristics including gender, age at analysis, Durie and Salmon, Binet or Dukes stage, first diagnosis, primary tumor, sites of metastases, therapy, paraprotein, and frequency of T_reg cells. (f: female, m: male; therapy: A: Doxorubicin, BMT: autologous bone-marrow transplantation, C: Cyclophosphamide, I: Idarubicin, M: Melphalan, V: Vincristine, D: Prednisone, T: Thalidomide, no tx: no therapy, n.a.: not accessible.)